^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Ektomab (TRBS07)

    i
    Other names: TRBS07
    Associations

    News

    Trials
    Company:
    Trion Pharma
    Drug class:
    CD3 agonist, GD2 ganglioside inhibitor, GD3 ganglioside inhibitor
    Related drugs:
    Associations

    News

    Trials
    over3years
    GD2-directed bispecific trifunctional antibody outperforms dinutuximab beta in a murine model for aggressive metastasized neuroblastoma. (PubMed, J Immunother Cancer)
    Here we provide proof-of-concept for EKTOMUN preclinical efficacy against neuroblastoma, presenting this bispecific trAb as a promising new agent to fight neuroblastoma.
    Preclinical • Journal
    |
    CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    Qarziba (dinutuximab beta) • Ektomab (TRBS07)